Pseudomonas aeruginosa carries multiresistance plasmids less often than does Klebsiella pneumoniae, develops mutational resistance to cephalosporins less readily than Enterobacter species, and has less inherent resistance than Stenotrophomonas maltophilia. What nevertheless makes P. aeruginosa uniquely problematic is a combination of the following: the species' inherent resistance to many drug classes; its ability to acquire resistance, via mutations, to all relevant treatments; its high and increasing rates of resistance locally; and its frequent role in serious infections. A few isolates of P. aeruginosa are resistant to all reliable antibiotics, and this problem seems likely to grow with the emergence of integrins that carry gene cassettes encoding both carbapenemases and amikacin acetyltransferases.
Although efflux is the greater factor, the role of impermeability in pseudomonal resistance was confirmed recently by Li et al. [4] , who showed that membrane disorganizers, such as EDTA, potentiated antibiotics, especially in the absence of MexABOprM. The MICs for a highly permeable and MexAB-OprMdeficient mutant were as follows: carbenicillin, 0.0125 mg/L; ciprofloxacin, 0.03 mg/L; tetracycline, 0.015 mg/L; and chloramphenicol, 0.5 mg/L. These MIC values are considerably less than those for clinical isolates. This impermeability can be reconciled with copious production of OprF if many pores are nonfunctional or if they adopt a smaller diameter in the membrane than in reconstituted liposomes.
MUTATIONS AND RESISTANCE
Various penicillins, cephalosporins, carbapenems, monobactams, aminoglycosides, fluoroquinolones, and polymyxins overcome the inherent defenses of P. aeruginosa and are active against most isolates. All, however, are prone to being compromised by mutational resistance (table 1) . Mutations to topoisomerases II and IV confer fluoroquinolone resistance more readily in P. aeruginosa than in Enterobacteriaceae, because P. aeruginosa has poorer inherent susceptibility [5] . Derepression of the chromosomal AmpC b-lactamase reduces susceptibility to penicillins and cephalosporins, although the level of resistance depends on the degree of derepression, which is more variable than that in Enterobacter mutants [1] . The up-regulation of MexAB-OprM compromises Three-component efflux pump. The pump itself (MexB, MexD, or MexF, according to the system) lies in the cytoplasmic membrane and is attached via a linker lipoprotein (MexA, MexC, or MexE) to the exit portal (OprM, OprJ, or OprN). Efflux system components appear in large roman type; other membrane components appear in small italic type. 
Agl, aminoglycosides; Azl, azlocillin; Atm, aztreonam; Carb, carbenicillin, Czid, ceftazidime, Cpm, cefepime; Cpr, cefpirome; Fq, fluoroquinolone; Imi, imipenem; Mero, meropenem; Pip, piperacillin; Pm, polymyxin; r, reduced susceptibility; R, frank resistance, which may vary in its distinction from "r," according to the breakpoints adopted; Tic, ticarcillin. the fluoroquinolones, penicillins, cephalosporins, and, to some extent, meropenem (although not imipenem), and it also enhances resistance to many other drugs that lack useful antipseudomonal activity [3, 6] . Up-regulation of other efflux systems-for example, MexCD-OprJ and MexEF-OprN-confers resistance to fluoroquinolones and some b-lactams; up-regulation of MexXY-OprM also affects aminoglycosides. Genome sequencing suggests that there are at least 5 additional efflux systems, all of which await characterization [3] .
Permeability mutations are widely blamed for increased resistance to b-lactams and fluoroquinolones, but, again, much of what was once attributed to impermeability is now understood to reflect up-regulated efflux. Reduced expression of OprF has only a slight effect on the MICs of b-lactams and fluoroquinolones [7] . There is better evidence that increased impermeability is a mechanism of aminoglycoside resistancefor example, in the "small-colony variants" that are sometimes selected during gentamicin therapy and in isolates with reduced susceptibility to all aminoglycosides [8] . Because these latter organisms lack modifying enzymes and are not cross-resistant to fluoroquinolones or b-lactams, impermeability is more likely to be the mechanism of resistance than is up-regulation of MexXY-OprM, which affects other antibiotic classes in addition to aminoglycosides (table 1) .
Mutational impermeability is important in resistance to carbapenems and arises via the loss of OprD, a porin that forms narrow transmembrane channels that are accessible to carbapenems but not to other b-lactams [9] . Loss of OprD is associated with resistance to imipenem and reduced susceptibility to meropenem. To complicate matters, OprD is coregulated with MexEF-OprN; thus, the nfxc (mexT) mutants that occasionally are selected by fluoroquinolones (not carbapenems) have (1) up-regulated MexEF-OprN and reduced OprD, with consequent resistance to both fluoroquinolones and imipenem, and (2) reduced susceptibility to meropenem [10] . Polymyxins were long thought to evade stable mutational resistance, but MICs of 128-256 mg/L have been noted for a few isolates from patients with cystic fibrosis, who receive the nebulized drug for 
NOTE.
Azl, azlocillin; Carb, carbenicillin, Clv, clavulanate; Cpm, cefepime; Cpr, cefpirome; Imi, imipenem; Czid, ceftazidime; Mero, meropenem; Pip, piperacillin; r, reduced susceptibility; R, frank resistance, which may vary in its distinction from "r," according to the breakpoints adopted, the permeability of the strain, and the amount of enzyme produced; S, susceptible; Taz, tazobactam; Tic, ticarcillin.
long periods. The mechanisms at work are unclear, but they probably involve changes to membrane architecture.
MULTIPLE MUTATIONS AND MULTIDRUG RESISTANCE
No single mutation compromises every antipseudomonal drug. Nevertheless, up-regulated efflux can simultaneously compromise fluoroquinolones and most b-lactams, leaving only the aminoglycosides (which lack reliable efficacy as antipseudomonal monotherapy) and imipenem (to which mutational resistance evolves at high frequency). A combination of upregulated efflux, loss of OprD, and impermeability to aminoglycosides compromises every drug class except the polymyxins. Each of the necessary mutations arises in 1 cell per 10 7 to 10 9 cells, and, although simultaneous emergence is mathematically and biologically improbable, sequential emergence is all too likely because infections that are resistant to the first antibiotic administered are likely to be treated with a second antibiotic, and so on. Mutations that up-regulate efflux may act additively with those that effect permeability, b-lactamase expression, or topoisomerase susceptibility so as to exacerbate resistance [11] . Accumulation of sequential mutations may be facilitated by hypermutators, which either lack the ability to perform DNA proofreading or mismatch repair, or which use DNA polymerases with a reduced copying fidelity. Because resistance is most likely to emerge in hypermutators, antibiotics may select for hypermutators, thereby increasing the probability that further resistance will emerge. Hypermutators were found in sputum samples obtained from 11 of 30 patients who had cystic fibrosis and chronic P. aeruginosa infections, compared with 0 of 75 samples from patients without cystic fibrosis who had acute infections [12] .
ACQUIRED GENES AND MULTIDRUG RESISTANCE
Many acquired b-lactamases and aminoglycoside-modifying enzymes have been noted in P. aeruginosa. Some of these are widely prevalent among isolates from southern Europe, Turkey, and Southeast Asia, although they are not widely prevalent in the United Kingdom. The most frequently acquired b-lactamases are PSE-1 and PSE-4. Like classical TEM and OXA enzymes (which also occur, albeit rarely, in P. aeruginosa), these PSE enzymes can be circumvented with the use of carbapenems, oxyimino-aminothiazolyl cephalosporins (e.g., ceftazidime, cefepime, or cefpirome) or with monobactams [1] . However, blactamases that give wider resistance are emerging in P. aeruginosa. PER-1 b-lactamase and the extended-spectrum OXA types (known as OXA-extended-spectrum b-lactams, or OXAESBLs) deserve discussion, as do the IMP and VIM metallo-blactamases (table 2) .
PER-1, a class A b-lactamase, confers high-level resistance to ceftazidime, with susceptibility restored by the addition of clavulanate, but it has little in vitro effect on piperacillin; carbapenems are stable. PER-1 is frequently noted in P. aeruginosa from Turkey [13] , and it occasionally has been found in Europe. OXA-ESBLs, like PER-1, mainly are reported in P. aeruginosa from Turkey and include OXA-11, -14, -16, -17, -19, and -28 mutants of OXA-10, as well as the OXA-15 mutant of OXA-2 [14, 15] . Like TEM and SHV ESBLs, the OXA ESBLs have minor sequence substitutions that greatly extend their hydrolytic spectra. All give resistance to oxyimino-aminothiazolyl cephalosporins, monobactams, and penicillins, but not to carbapenems. A few P. aeruginosa isolates from Turkey produce both PER enzymes and ESBLs, often together with potent aminoglycoside-modifying enzymes [16] .
IMP and VIM are metallo-b-lactamases that rapidly hydrolyze penicillins, cephalosporins, and carbapenems-but not az- NOTE. US data are from The Surveillance Network Database USA (TSN; Focus Technologies). All US data, except for the data on resistance to piperacillin among CF sputum isolates, are for 11000 isolates. More than 1250 US hospitals participated; 170,000 isolates were tested, but not all were tested with every antibiotic. UK data are from Henwood et al. [22] and are based on a survey of 2194 isolates from 25 hospitals. All isolates were tested with every antibiotic, with 1100 isolates per group. CF sputum, sputum isolates from patients with cystic fibrosis; ICU, intensive care unit.
a Several breakpoints of the British Society for Antimicrobial Chemotherapy are more conservative than those of the National Committee for Clinical Laboratory Standards, which means that comparisons between the countries require caution. treonam [17] . Resistance to penicillins and cephalosporins usually accompanies production, but carbapenem resistance may also require the loss of OprD. Since 1988, IMP-1 has been found in Japan, where it is now widely scattered-although still rare-among P. aeruginosa strains [18] . It has not been found among P. aeruginosa strains elsewhere; however, a related enzyme, IMP-7, was noted in P. aeruginosa in Canada [19] , whereas IMP-2, -3, -4, -5, -6, and -8 were found in other species and countries [17] . VIM-1 was found in P. aeruginosa in Italy. VIM-2, the amino acid sequence of which is 90% homologous to that of VIM-1, has since been found in France, Greece, and South Korea, whilst VIM-3 has been found in Taiwan. VIM enzymes resemble IMP types with regard to their hydrolytic properties, they but share only 30%-40% amino acid identity [17] .
The genes for VIM and IMP enzymes, like those for OXAESBLs, are often carried as cassettes within integrins, which are natural recombination systems that assemble series of acquired genes behind a single promoter. This organization facilitates gene recombination. Critically, the b-lactamase genes are often adjacent to aminoglycoside 6 -N acetyltransferase [aac(6 )-1b] determinants [17, 20, 21] . A P. aeruginosa strain with this combination of cassettes is susceptible only to polymyxins, ciprofloxacin, and, perhaps, aztreonam. If MexAB-OprM is up-reg- ulated by mutation, or if the isolate has topoisomerase and ampD mutations, then only susceptibility to polymyxins remains.
PREVALENCE OF RESISTANCE AND MULTIDRUG RESISTANCE
Relevant b-lactams and aminoglycosides remain active against 70%-98% of P. aeruginosa isolates in the United States and the United Kingdom (tables 3 and 4). Nevertheless, resistance is more frequent locally-most notably, in units for the management of patients with burns or cystic fibrosis or in intensive care units. The excess of aminoglycoside resistance in isolates from patients with cystic fibrosis is striking in both the United Kingdom and the United States (table 3) , as is the excess of imipenem resistance among isolates from patients in intensive care units. More generally, there is an excess of resistance among isolates from hospitalized patients, compared with those from outpatients. Snapshot surveys performed in 1982, 1993, and 1999 show little increase in resistance among P. aeruginosa strains in the United Kingdom [22] ; however, resistance-to ciprofloxacin in particular but, also, to piperacillin and gentamicin-has recently risen among such strains in the United States (figure 2).
Much resistance is concentrated in a few strains. Itokazu et al. [23] compared ceftazidime-resistant (14.2%) and ceftazidime-susceptible (85.8%) organisms among a total of 6675 P. aeruginosa isolates collected from patients in intensive care units across the United States from 1990 to 1993. Isolates that were resistant to ceftazidime had higher rates of resistance to gentamicin (54.5% resistance to gentamcin vs. 31.7% among those susceptible to to ceftazidime), amikacin (26.9% vs. 7.8%), and imipenem (26.4% vs. 10.1%), despite the fact that resistance to aminoglycosides and imipenem is mechanistically independent of most ceftazidime resistance (table 1). The P. aeruginosa data collected by The Surveillance Network Database USA (Focus Technologies; Herndon, VA) likewise show rising proportions of isolates that are resistant to multiple antibiotics, with ∼16% of isolates now resistant to у3 of the core drugs (amikacin, ceftazidime, ciprofloxacin, gentamicin, imipenem, and piperacillin-ticarcillin) and with 1% resistant to all 6 of these agents (table 4). It seems likely that most of this multidrug resistance reflects the accumulation of multiple mutations, although this surmise remains to be confirmed by molecular studies, and although reports from other parts of the world document extreme multidrug resistance associated with acquired resistance genes.
In a hospital in Thessaloniki, Greece, a serotype O:12 strain 
PREVENTING AND MANAGING MULTIDRUG RESISTANCE
The selection of resistant mutants, a risk associated with any antipseudomonal therapy, varies with the type and dosage of antibiotic used and the infection site. Carmeli et al. [25] found a 2-fold greater risk of selection for resistance when imipenem, rather than ciprofloxacin, ceftazidime, or piperacillin, was used; however, translation of this observation into risk management is complicated by the fact that the mechanism of resistance to imipenem is narrow in spectrum and, arguably, is less disturbing than the broader-spectrum mechanisms of resistance selected by other antibiotics. Against drug-susceptible P. aeruginosa, there is a strong argument for the use of meropenem rather than other b-lactams, because development of frank resistance to meropenem requires 2 mutations (up-regulated efflux and loss of OprD), whereas resistance to other drugs can arise as a result of single mutations. The differences in pseudomonal behavior in response to meropenem and imipenem have been discussed extensively elsewhere [26] . It is often assumed that combination therapy will prevent the selection of mutational resistance, but evidence for this is scanty. In addition, single efflux mutations may affect both the b-lactams and the fluoroquinolones, thereby undermining the use of combinations of these drugs (table 1) . The original emergence of multidrug resistance in association with plasmids and integrins is less predictable than mutational resistance because it depends on the random escape of genes to mobile DNA. However, once such resistance has emerged, either the host strain can spread among patients or the resistance can disseminate among strains. The former situation occurs more frequently, as with the dissemination of P. aeruginosa of serotype O:12 with the VIM-2 enzyme in Thessaloniki, Greece [24] . In such cases, the best answers to preventing dissemination of resistance are infection control and elimination of the unnecessary use of broad-spectrum antibiotics. In a few cases-for example, in outbreaks involving VIM-2 in Korea, IMP-1 in Japan, and PER-1 in Turkey-plasmids coding potent b-lactamases together with aminoglycoside-modifying enzymes have disseminated among P. aeruginosa strains, rendering control even more difficult.
When strains have multiple mutational or acquired resistances, the choice of therapy is often frighteningly limited, especially because most clinicians would prefer to use a synergistic combination for serious pseudomonal infections. No new fluoroquinolone offers better antipseudomonal activity than does ciprofloxacin, and none retains activity against ciprofloxacin-resistant isolates. Where resistance is mutational, tobramycin and meropenem are the drugs most likely to retain activity, because they are the aminoglycoside and the b-lactam with the best inherent activity against P. aeruginosa. Isolates with efflux-mediated resistance to meropenem, penicillins, and cephalosporins might, however, retain susceptibility to imipenem, and, although meropenem is usually the more active carbapenem, this possibility should always be considered. Carbapenems retain activity against isolates with PER enzymes and ESBLs, and monobactams retain activity against some isolates with IMP or VIM enzymes. Isepamicin (an aminoglycoside that is often available for compassionate use, even in areas where it is not licensed for such use) evades the aminoglycosidemodifying AAC(6 ) enzymes that often accompany potent blactamases and might be worth considering.
In instances in which all chances of b-lactam, aminoglycoside, and quinolone use are lost, the polymyxins remain drugs of last resort; despite their significant toxicity, they have been used with some success. Levin et al. [27] reported that the use of intravenous polymyxin E (colistin) was successful in 35 (58%) of 60 patients treated for multidrug-resistant Pseudomonas and Acinetobacter infections, although it was associated with a failure rate of 75% when used for the treatment of pneumonias.
Perhaps most disturbing is the dearth of new drug options. Clinafloxacin was slightly more active than ciprofloxacin, but its development has been suspended, and no other antipseudomonal antibiotic is in advanced development. For the long term, multidrug efflux inhibitors are promising for use with fluoroquinolones or b-lactams [28] , and metallo-b-lactamase inhibitors [29] are the focus of laboratory investigation. Unless new drugs are developed, it is hard to escape the conclusion that multidrug-resistant Pseudomonas strains will be an increasing reality and that the use of polymyxins will increase, despite their toxicity.
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